NASDAQ : CBLI

Cytocom, Inc.

$3.17 USD

-$0.25 (-7.31%)

Volume
116.26K
Average Volume
156.95K
Market Capitalization
$226.39M
P/E Ratio
-16.68
Dividend Yield
0.00%
Price Target
Year High
$5.64
Year Low
$2.70
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$7.60
Company Overview

NASDAQ

Yakov Kogan

Biotechnology

Healthcare

CBLI

18

US

USD

http://www.cytocom.com

17168496810

185860202

0001318641

Liquidity Metrics

0.00

7.60

7.60

6.39

0.00

Sales & Valuation

$262.94K

860.98

19.52

-95.40

-0.19

Profitability

-$0.19

-$2.4M

-912.16%

-855.62%

-160.02%

-103.47%

P/E Metrics

-16.68

2.31

2.31

Analyst Price Target & Rating

N/A

0/5

4 Analysts

%

Poll Results

About Cytocom, Inc. (NASDAQ:CBLI) Stock

Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in the discovery and advancement of therapeutic drugs. Based in Buffalo, New York, the organization maintains a modest workforce of 15 full-time employees. Its primary objective involves pioneering methods to stimulate the body's immune defenses to tackle significant medical challenges. A core component of its work is a platform utilizing Toll-like immune receptor activators, which demonstrates utility in both alleviating radiation-induced damage and in the field of immuno-oncology. The most advanced therapeutic candidate in its pipeline is Entolimod, an immune-stimulating compound currently under development as a protective measure against radiation exposure and as an immunotherapy for various cancers and other in ... dications. The company's portfolio also encompasses other promising products, including CBLB612, Mobilan, and CBL0137. CBLB612 is formulated from a natural stimulant that targets a specific component of the innate immune system: the heterodimeric receptor formed by toll-like receptors 2 (TLR2) and 6 (TLR6). Mobilan is a recombinant, non-replicating adenovirus engineered to induce the expression of TLR5 and its corresponding agonistic ligand. Lastly, CBL0137 is a small molecule characterized by a multi-faceted mechanism of action, suggesting its potential effectiveness across diverse forms of cancer.

Frequently Asked Questions

What is the current Cytocom, Inc. (CBLI) stock price?

Cytocom, Inc.(NASDAQ:CBLI) stock price is $3.17 in the last trading session. During the trading session, CBLI stock reached the peak price of $3.5 while $3.11 was the lowest point it dropped to. The percentage change in CBLI stock occurred in the recent session was --7.31% while the dollar amount for the price change in CBLI stock was -$0.25.

CBLI's industry and sector of operation?

The NASDAQ listed CBLI is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of CBLI?

|
|
|
|
|

How many employees does CBLI have?

Number of CBLI employees currently stands at 18. CBLI operates from 73 High St, Buffalo, NY , US.

Link for CBLI official website?

Official Website of CBLI is: http://www.cytocom.com

How do I contact CBLI?

CBLI could be contacted at phone #17168496810 and can also be accessed through its website. CBLI operates from 73 High St, Buffalo, NY , US.

How many shares of CBLI are traded daily?

The average number of CBLI shares traded daily for last 3 months was 156.95K.

What is the market cap of CBLI currently?

The market value of CBLI currently stands at $226.39M with its latest stock price at $3.17